Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
Active, not recruiting · NCT02912208 · Registry updated 2022-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes | Cytopenia, Hemic and Lymphatic Diseases, blood platelet disease, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, thrombocytopenia | Active, not recruiting | Phase 2 | 2022-01-28 | NCT02912208 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Associazione Qol-one | 3 |
64 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.